Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Solid Malignant Neoplasm
98%
Malignant Neoplasm
93%
Clinical Trial
91%
Advanced Cancer
77%
Diseases
71%
Adverse Event
50%
Pembrolizumab
38%
Overall Survival
38%
Phase I Trials
36%
Progression Free Survival
31%
Maximum Tolerated Dose
30%
Bevacizumab
28%
Immunotherapy
25%
Immune Checkpoint Inhibitor
25%
Paclitaxel
24%
Monotherapy
22%
Antitumor Activity
22%
Pharmacokinetic
22%
Selinexor
21%
Non Small Cell Lung Cancer
19%
Combination Therapy
18%
Temsirolimus
17%
Melanoma
17%
Colorectal Carcinoma
17%
Mammalian Target of Rapamycin Inhibitor
16%
Carboplatin
15%
Pharmacodynamics
14%
Chemotherapy
14%
Thrombocytopenia
14%
Epidermal Growth Factor Receptor
14%
Vasculotropin
13%
Tolerability
13%
Diarrhea
13%
Biological Marker
11%
Prevalence
11%
Oxaliplatin
10%
Ovary Cancer
10%
Metastasis
10%
Breast Cancer
9%
Liver Metastasis
9%
Sorafenib
9%
Anemia
9%
Neutropenia
9%
Cetuximab
9%
Connective Tissue Cancer
9%
Rash
9%
Ipilimumab
8%
Pazopanib
8%
Lenalidomide
8%
Keyphrases
Advanced Solid Tumors
55%
Patients with Advanced Cancer
54%
Stable Disease
52%
Phase I Clinical Trial
45%
Partial Response
45%
Pembrolizumab
41%
Phase I Trial
40%
Phase I Study
37%
MD Anderson Cancer Center
33%
Immune Checkpoint Inhibitors
32%
Dose-limiting Toxicity
25%
Bevacizumab
24%
Center Experience
24%
Early Phase Clinical Trials
23%
Confidence Interval
22%
Tumor
22%
Advanced Malignancies
21%
Overall Survival
21%
Maximum Tolerated Dose
20%
Monotherapy
20%
Antitumor Activity
20%
MTOR Inhibitor
19%
Selinexor
19%
Clinical Outcomes
19%
Non-small Cell Lung Cancer (NSCLC)
18%
Solid Tumors
18%
PIK3CA mutation
18%
Targeted Therapy
18%
Treatment-related Adverse Events
18%
Temsirolimus
17%
Clinical Benefit
17%
Programmed Death-ligand 1 (PD-L1)
16%
Paclitaxel
16%
Progression-free Survival
16%
Mammalian Target of Rapamycin (mTOR)
16%
Adverse Events
15%
Clinical Trials
15%
Tumor Subtype
15%
Dose Escalation
15%
In Cancer
14%
Median Overall Survival
14%
Dose Level
14%
Advanced Cancer
14%
Metastatic Tumor
14%
Tolerability
13%
Complete Response
12%
Dose-escalation Study
12%
Median Progression-free Survival
12%
Advanced or Metastatic
12%
Carboplatin
12%
Medicine and Dentistry
Clinical Trial
77%
Malignant Neoplasm
71%
Neoplasm
61%
Diseases
51%
Cancer
51%
Advanced Cancer
44%
Overall Survival
34%
Immune Checkpoint Inhibitor
30%
Pembrolizumab
30%
Progression Free Survival
30%
Solid Malignant Neoplasm
29%
Targeted Therapy
27%
Immunotherapy
25%
Adverse Event
21%
Phase I Trials
17%
Non Small Cell Lung Cancer
15%
Mammalian Target of Rapamycin Inhibitor
15%
Oncology
15%
Melanoma
13%
Colorectal Carcinoma
13%
Biological Marker
13%
Immunity
12%
Mammalian Target of Rapamycin
12%
Temsirolimus
12%
Metastatic Carcinoma
11%
Prevalence
11%
Adrenal Cortex Carcinoma
11%
Systemic Therapy
11%
Combination Therapy
10%
Selinexor
9%
Ovarian Cancer
9%
Immune-Related Adverse Events
9%
Connective Tissue Cancer
9%
Next Generation Sequencing
9%
Bevacizumab
9%
Ewing Sarcoma
8%
Pneumonia
8%
Epidermal Growth Factor Receptor
8%
PI3K/AKT/mTOR Pathway
8%
Hazard Ratio
7%
Thrombocytopenia
7%
Multivariate Analysis
7%
Monotherapy
7%
Squamous Cell Carcinoma
7%
Patient Referral
7%
Cancer Therapy
6%
Paclitaxel
6%
Rapamycin
6%
Cixutumumab
6%
Somatomedin
6%